Evidence map›Paper›PMID 38423595›Full record

ArticleCancer genomics & proteomics

Impact of Tumor Grade Distribution on Genetic Alterations in Clear Cell Renal Cell Carcinoma and Prostate Cancer.

Kosuke Mizutani, Seiji Sugiyama, Koji Kameyama, Shingo Kamei, Shigeaki Yokoi, Akemi Morikawa, Makoto Takeuchi, Kensaku Seike, Toru Yamada, Hidetoshi Ehara and 10 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Prognostic Significance ofCancer genomics & proteomics · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

Kosuke MizutaniDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan; k-mizutani@cjimc-hp.jp.
Seiji SugiyamaDepartment of Pathology, Central Japan International Medical Center, Minokamo, Japan.
Koji KameyamaDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Shingo KameiDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Shigeaki YokoiDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Akemi MorikawaDepartment of Breast Surgery, Central Japan International Medical Center, Minokamo, Japan.
Makoto TakeuchiDepartment of Breast Surgery, Central Japan International Medical Center, Minokamo, Japan.
Kensaku SeikeDepartment of Urology, Chuno Kosei Hospital, Seki, Japan.
Toru YamadaDepartment of Urology, Tokai Central Hospital, Kakamigahara, Japan.
Hidetoshi EharaDepartment of Urology, Asahi University Hospital, Gifu, Japan.
Seiya SawadaCancer Genomic Testing & Treatment Center, Central Japan International Medical Center, Minokamo, Japan.
Kouseki HiradeCancer Genomic Testing & Treatment Center, Central Japan International Medical Center, Minokamo, Japan.
Hirohito FurutaDepartment of Clinical Laboratory, Central Japan International Medical Center, Minokamo, Japan.
Kengo MatsunagaDepartment of Pathology, Central Japan International Medical Center, Minokamo, Japan.
Tetsuya YamadaDepartment of Pathology, Central Japan International Medical Center, Minokamo, Japan.
Ippei SakamotoBioinformatics Department, Communication Engineering Center, Electronic Systems Business Group, Mitsubishi Electric Software Corporation, Hamamatsu-cho, Japan.
Yasutaka KatoGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Shinjuku, Japan.
Hiroshi NishiharaGenomics Unit, Keio Cancer Center, Keio University School of Medicine, Shinjuku, Japan.
Satoshi IshiharaDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Takashi DeguchiDepartment of Urology, Central Japan International Medical Center, Minokamo, Japan.
Saitama International Medical Center · JPKeio University · JPTokai Central Hospital · JPAsahi University · JPMitsubishi Electric (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimA genomic analysis based on next-generation sequencing is important for deciding cancer treatment strategies. Cancer tissue sometimes displays intratumor heterogeneity and a pathologic specimen may contain more than two tumor grades. Although tumor grades are very important for the cancer prognosis, the impact of higher tumor grade distribution in a specimen used for a genomic analysis is unknown. PATIENTS AND

methodsWe retrospectively analyzed the data of 61 clear cell carcinoma and 46 prostate cancer patients that were diagnosed between December 2018 and August 2022 using the GeneRead Human Comprehensive Cancer Panel or SureSelect PrePool custom Tier2. Genome annotation and curation were performed using the GenomeJack software.

resultsTumor mutation burden (TMB) was increased in proportion to the higher tumor grade distribution in grade 2 clear cell renal cell carcinoma (ccRCC). In PC, Grade Group 3/4 specimens that included an increased distribution of Gleason pattern 4 had more frequent gene mutations.

conclusionOur results suggest the importance of selecting the maximum distribution of higher tumor grade areas to obtain results on the precise gene alterations for genomics-focused treatments.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsProstatic NeoplasmsHumansMaleMutationRetrospective Studiescancer panel testgenetic alterationintratumor heterogeneityTumor grade distribution

Identifiers

PMID38423595
PMCPMC10905277
OpenAlexW4392285081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.